Data Insights

Lenvatinib mesylate by Eisai for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Gastrointestinal Stromal Tumor (GIST)

Data Insights

Lenvatinib mesylate by Eisai for Acral Lentiginous Melanoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Acral Lentiginous Melanoma

Data Insights

Lenvatinib mesylate by Eisai for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Lenvatinib mesylate by Eisai for Ovarian Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Ovarian Cancer

Data Insights

Lenvatinib mesylate by Eisai for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Triple-Negative Breast Cancer (TNBC)

Data Insights

Lenvatinib mesylate by Eisai for Lung Adenocarcinoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Lung Adenocarcinoma

Data Insights

Lenvatinib mesylate by Eisai for Bladder Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase III for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Bladder Cancer

Data Insights

Lenvatinib mesylate by Eisai for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Lenvatinib mesylate by Eisai for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Lenvatinib mesylate by Eisai for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer)....

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

Lenvatinib mesylate by Eisai for Neuroendocrine Carcinoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Neuroendocrine Carcinoma

Data Insights

Lenvatinib mesylate by Eisai for Merkel Cell Carcinoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Merkel Cell Carcinoma

Data Insights

Lenvatinib mesylate by Eisai for High-Grade Glioma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in High-Grade Glioma

Data Insights

Lenvatinib mesylate by Eisai for Rhabdomyosarcoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Rhabdomyosarcoma

Data Insights

Lenvatinib mesylate by Eisai for Non-Small Cell Lung Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Non-Small Cell Lung Cancer

Data Insights

Lenvatinib mesylate by Eisai for Ewing Sarcoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Ewing Sarcoma

Data Insights

Lenvatinib mesylate by Eisai for Metastatic Melanoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Metastatic Melanoma

Data Insights

Lenvatinib mesylate by Eisai for Colorectal Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Colorectal Cancer

Data Insights

Lenvatinib mesylate by Eisai for Osteosarcoma: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Osteosarcoma

Data Insights

Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Metastatic Biliary Tract Cancer